Skip to content

09995.HK

RemeGen Co., Ltd.

HKSE · Healthcare · Biotechnology · CN

HKD 64.85
+2.37%
Ask drillr

Year over year

Reported trailing growth

Revenue
+283.5%
EBITDA
+729.6%
EBIT
+531.9%
EPS
+591.5%
Free cash flow
+654.6%
Operating cash flow
+934.2%

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
—

Three-year CAGR

Revenue
+61.6%
EBITDA
+138.4%
EBIT
+110.7%
Net income
+148.3%
EPS
+147.3%
Free cash flow
+89.8%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026